个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Deubiquitinating enzyme OTUD4 regulates metastasis in triple-negative breast cancer by stabilizing Snail1

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ SCIE

作者：
Ma Xiuqing[1] * ; Wan Rui[1] * ; Wen Yalei[2] * ; Liu Tongzheng[1,*2] ; Song Yan[3,*3] ; Zhu Yingjie[1,*1] ;
机构： [1]College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, China [2]Guangdong Second Provincial General Hospital, Research Institute for Maternal and Child Health, Jinan University, Guangzhou, China [3]Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical, Sciences and Peking Union Medical College, Beijing, China
出处：
DOI： 10.1016/j.yexcr.2023.113864
ISSN：

关键词： OTUD4 Triple-negative breast cancer Snail1 Metastasis Deubiquitination

摘要：
Metastasis is the primary cause of cancer-related deaths and remains poorly understood. Deubiquitinase OTU domain containing 4 (OTUD4) has been reported to regulate antiviral immune responses and resistance to radio- or chemo-therapies in certain cancers. However, the role of OTUD4 in cancer metastasis remain unknown. Here, we demonstrate that the depletion of OTUD4 in triple-negative breast cancer (TNBC) cells markedly suppress cell clonogenic ability, migration, invasion and cancer stem cell population in vitro as well as metastasis in vivo. Mechanistically, the tumor promoting function of OTUD4 is mainly mediated by deuiquitinating and stabilizing Snail1, one key transcriptional factor in the epithelial-mesenchymal transition. The inhibitory effect of targeting OTUD4 could be largely reversed by the reconstitution of Snail1 in OTUD4-deficient cells. Overall, our study establishes the OTUD4-Snail1 axis as an important regulatory mechanism of breast cancer metastasis and provides a rationale for potential therapeutic interventions in the treatment of TNBC.Copyright © 2023 Elsevier Inc. All rights reserved.

基金：
This work was supported by the Science and Technology Project of Guangdong Province (2023A0505050149), National Natural Science Foundation of China (81773758 and 81603133), Guangdong Basic and Applied Basic Research Foundation (2022A1515012371, 2019A1515011934 and 2021A1515011233), Guangzhou Basic Research Program Basic and Applied Basic Research Project (2023A04J0645), Major Talent Program of Guangdong Provincial (2019QN01Y933), the project of State Key Laboratory of Functions and Applications of Medicinal Plants, Guizhou Medical University (QJJ [2022]420), Fundamental Research Funds for the Central Universities (21622102), Medical Joint Fund of Jinan University (YXJC2022006), National Key R&D Program of China (2022YFC2505003) and Beijing Hope Run Special Fund of Cancer Foundation of China (LC2020A08).
语种：
外文
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类 | 3 区 生物学
小类 | 4 区 细胞生物学 4 区 肿瘤学
最新[2025]版：
大类 | 3 区 生物学
小类 | 4 区 细胞生物学 4 区 肿瘤学
JCR分区：
出版当年[2022]版：
Q2 ONCOLOGY Q3 CELL BIOLOGY
最新[2023]版：
Q2 ONCOLOGY Q3 CELL BIOLOGY

影响因子： 最新[2023版] 最新五年平均 出版当年[2022版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, China
共同第一作者：
通讯作者：
通讯机构： [1]College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, Guangzhou, China [3]Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical, Sciences and Peking Union Medical College, Beijing, China [*1]College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, No. 601 Huangpu Road West, Guangzhou, 510632, China. [*2]College of Pharmacy/International Cooperative Laboratory of Traditional Chinese Medicine Modernization and Innovative Drug Development of Ministry of Education (MOE) of China, Jinan University, No. 601 Huangpu Road West, Guangzhou, 510632, China [*3]National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical, Sciences and Peking Union Medical College, No. 17 Panjiayuan Nanli, Chaoyang District, Beijing, 100021, China.
推荐引用方式(GB/T 7714)：
Ma Xiuqing,Wan Rui,Wen Yalei,et al.Deubiquitinating enzyme OTUD4 regulates metastasis in triple-negative breast cancer by stabilizing Snail1[J].EXPERIMENTAL CELL RESEARCH.2024,434(1):113864.doi:10.1016/j.yexcr.2023.113864.
APA：
Ma Xiuqing,Wan Rui,Wen Yalei,Liu Tongzheng,Song Yan&Zhu Yingjie.(2024).Deubiquitinating enzyme OTUD4 regulates metastasis in triple-negative breast cancer by stabilizing Snail1.EXPERIMENTAL CELL RESEARCH,434,(1)
MLA：
Ma Xiuqing,et al."Deubiquitinating enzyme OTUD4 regulates metastasis in triple-negative breast cancer by stabilizing Snail1".EXPERIMENTAL CELL RESEARCH 434..1(2024):113864

相关文献

[1]A novel axis of circKIF4A-miR-637-STAT3 promotes brain metastasis in triple-negative breast cancer [2]Sanguisorba officinalis L Suppresses Triple-Negative Breast Cancer Metastasis by Inhibiting Late-Phase Autophagy via Hif-1α/Caveolin-1 Signaling [3]Prospects of Immunotherapy for Triple-Negative Breast Cancer. [4]Bruceine A: Suppressing metastasis via MEK/ERK pathway and invoking mitochondrial apoptosis in triple-negative breast cancer [5]Integrin α9 depletion promotes β-catenin degradation to suppress triple-negative breast cancer tumor growth and metastasis. [6]Effect of Huaier Granule on Adjuvant Treatment for High-risk Early-stage Triple-negative Breast Cancer [7]Nanoparticle drug delivery systems responsive to tumor microenvironment: Promising alternatives in the treatment of triple-negative breast cancer [8]Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGFβ signaling pathway (vol 560, 216142, 2023) [9]Discovery of YH677 as a cancer stemness inhibitor that suppresses triple-negative breast cancer growth and metastasis by regulating the TGF? signaling pathway [10]Rujifang inhibits triple-negative breast cancer growth via the PI3K/AKT pathway

资源点击量：2018 今日访问量：0 总访问量：645 更新日期：2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持：重庆聚合科技有限公司 地址：广州市越秀区大德路111号